The company said, “Iovance is reiterating total product revenue guidance within the range of $250 to $300 million in the first full calendar year of Amtagvi sales. The forecast continues to track in line with current and expected ATC growth trajectories, including large community practices and community referral activities. Proleukin sales are also expected to accelerate in the second half of 2025 from restocking at U.S. distributors, ex-U.S. demand, and sales growth for clinical and manufacturing uses. Iovance expects continued growth in total product revenue for the full year 2026 and beyond. Gross margins are expected to increase through near-term optimization of manufacturing capacity utilization over the next several years.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics options imply 23.8% move in share price post-earnings
- Iovance Biotherapeutics Advances Lifileucel Study for Endometrial Cancer
- Unusually active option classes on open July 23rd
- Iovance Biotherapeutics Gains Competitive Edge as Replimune Faces FDA Setback
- Realty Income, GitLab, DoorDash, Iovance, Senseonics: Trending by Analysts